Pain Following Tumor Removal Reduced By Single-Site Laparoscopic Surgery
10/01/2012
Researchers at the University of California, San Diego School of Medicine have found that recovery from an emerging, minimally invasive surgical technique called Laparo-Endoscopic Single-Site Surgery (LESS) was less painful for kidney cancer patients than traditional laparoscopic surgery. Study results were published in the online edition of Urology...
Using a newly discovered cell technology, Georgetown University Medical Center researchers were able to identify an effective therapy for a patient with a rare type of lung tumor...
Testing New Technology That Could Aid In Breast Cancer Diagnosis & Treatment
10/01/2012
New optical imaging technology developed at Tufts University School of Engineering could give doctors new ways to both identify breast cancer and monitor individual patients' response to initial treatment of the disease. A five-year clinical study of the procedure, funded by a $3.5 million grant from the National Institutes of Health, is now underway at Tufts Medical Center in Boston...
For ALK-Positive Lung Cancer, Phase III Trial Shows Crizotinib Superior To Single-Agent Chemotherapy
9/30/2012
The results of a new phase III trial show that crizotinib, a targeted therapy, is a more effective treatment than standard chemotherapy for patients with advanced, ALK-positive lung cancer, researchers said at the ESMO 2012 Congress of the European Society for Medical Oncology in Vienna. Rearrangements of the anaplastic lymphoma kinase (ALK) gene are found in about 5% of all lung cancers...
New Weapons In The Fight Against Cancer
9/30/2012
Where are the most promising developments from first-in-human studies? Several new first-in-man studies for drugs targeted against a range of cancers were released at the ESMO 2012 Congress of the European Society for Medical Oncology in Vienna...
For ALK-Positive Lung Cancer, Phase III Trial Shows Crizotinib Superior To Single-Agent Chemotherapy
9/30/2012
The results of a new phase III trial show that crizotinib, a targeted therapy, is a more effective treatment than standard chemotherapy for patients with advanced, ALK-positive lung cancer, researchers said at the ESMO 2012 Congress of the European Society for Medical Oncology in Vienna. Rearrangements of the anaplastic lymphoma kinase (ALK) gene are found in about 5% of all lung cancers...
New Weapons In The Fight Against Cancer
9/30/2012
Where are the most promising developments from first-in-human studies? Several new first-in-man studies for drugs targeted against a range of cancers were released at the ESMO 2012 Congress of the European Society for Medical Oncology in Vienna...
Aggressive Cancer Exploits MYC Oncogene To Amplify Global Gene Activity
9/30/2012
For a cancer patient, over-expression of the MYC oncogene is a bad omen. Scientists have long known that in tumor cells, elevated levels of MYC's protein product, c-Myc, are associated with poor clinical outcomes, including increased rates of metastasis, recurrence, and mortality...
Aggressive Cancer Exploits MYC Oncogene To Amplify Global Gene Activity
9/30/2012
For a cancer patient, over-expression of the MYC oncogene is a bad omen. Scientists have long known that in tumor cells, elevated levels of MYC's protein product, c-Myc, are associated with poor clinical outcomes, including increased rates of metastasis, recurrence, and mortality...
The Immune System And Brain Tumors - Potential Breakthrough
9/30/2012
In what could be a breakthrough in the treatment of deadly brain tumors, a team of researchers from Barrow Neurological Institute and Arizona State University has discovered that the immune system reacts differently to different types of brain tissue, shedding light on why cancerous brain tumors are so difficult to treat...